- Home
- Publications
- Publication Search
- Publication Details
Title
Pancreatic Cancer Chemoresistance to Gemcitabine
Authors
Keywords
-
Journal
Cancers
Volume 9, Issue 12, Pages 157
Publisher
MDPI AG
Online
2017-11-17
DOI
10.3390/cancers9110157
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Fibroblast drug scavenging increases intratumoural gemcitabine accumulation in murine pancreas cancer
- (2017) E Hessmann et al. GUT
- The role of stromal cancer-associated fibroblasts in pancreatic cancer
- (2017) Dagny von Ahrens et al. Journal of Hematology & Oncology
- Microenvironment in determining chemo-resistance in pancreatic cancer: Neighborhood matters
- (2017) Patricia Dauer et al. PANCREATOLOGY
- Chemoresistance in pancreatic cancer: Emerging concepts
- (2017) Manu Gnanamony et al. Oncology Letters
- Development of a Gemcitabine-Polymer Conjugate with Prolonged Cytotoxicity against a Pancreatic Cancer Cell Line
- (2017) Fanny Joubert et al. ACS Macro Letters
- A phosphoramidate ProTide (NUC-1031) and acquired and intrinsic resistance to gemcitabine.
- (2017) C. McGuigan et al. JOURNAL OF CLINICAL ONCOLOGY
- Key role of pancreatic stellate cells in pancreatic cancer
- (2016) Srinivasa P. Pothula et al. CANCER LETTERS
- TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3
- (2016) Rachel A. Hesler et al. CARCINOGENESIS
- Current Standard and Future Perspectives in First- and Second-Line Treatment of Metastatic Pancreatic Adenocarcinoma
- (2016) Volker Ellenrieder et al. DIGESTION
- Loss of P53 Function Activates JAK2–STAT3 Signaling to Promote Pancreatic Tumor Growth, Stroma Modification, and Gemcitabine Resistance in Mice and Is Associated With Patient Survival
- (2016) Sonja M. Wörmann et al. GASTROENTEROLOGY
- Pancreatic cancer
- (2016) Terumi Kamisawa et al. LANCET
- SPARC-Independent Delivery of Nab-Paclitaxel without Depleting Tumor Stroma in Patient-Derived Pancreatic Cancer Xenografts
- (2016) H. Kim et al. MOLECULAR CANCER THERAPEUTICS
- Key players in pancreatic cancer-stroma interaction: Cancer-associated fibroblasts, endothelial and inflammatory cells
- (2016) Michael Friberg Bruun Nielsen et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Profile of MMP and TIMP Expression in Human Pancreatic Stellate Cells: Regulation by IL-1α and TGFβ and Implications for Migration of Pancreatic Cancer Cells
- (2016) Vegard Tjomsland et al. NEOPLASIA
- Pancreatic cancer
- (2016) Jorg Kleeff et al. Nature Reviews Disease Primers
- Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma – A population-based cohort study
- (2015) Knut J. Labori et al. ACTA ONCOLOGICA
- Does long-term survival exist in pancreatic adenocarcinoma?
- (2015) Myrte Zijlstra et al. ACTA ONCOLOGICA
- Biocompatible Glycopolymer Nanocapsules via Inverse Miniemulsion Periphery RAFT Polymerization for the Delivery of Gemcitabine
- (2015) Robert H. Utama et al. BIOMACROMOLECULES
- T Cells Engineered against a Native Antigen Can Surmount Immunologic and Physical Barriers to Treat Pancreatic Ductal Adenocarcinoma
- (2015) Ingunn M. Stromnes et al. CANCER CELL
- A first-in-human phase I and pharmacokinetic study of CP-4126 (CO-101), a nucleoside analogue, in patients with advanced solid tumours
- (2015) B. Venugopal et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial
- (2015) M. Hidalgo et al. CLINICAL CANCER RESEARCH
- Enhanced cellular uptake and intracellular drug controlled release of VESylated gemcitabine prodrug nanocapsules
- (2015) Yanfen Fang et al. COLLOIDS AND SURFACES B-BIOINTERFACES
- Gemcitabine resistance in pancreatic ductal adenocarcinoma
- (2015) Yoav Binenbaum et al. DRUG RESISTANCE UPDATES
- Pharmacological targeting of the protein synthesis mTOR/4E-BP1 pathway in cancer-associated fibroblasts abrogates pancreatic tumour chemoresistance
- (2015) C. Duluc et al. EMBO Molecular Medicine
- An in vitro and in vivo study of gemcitabine-loaded albumin nanoparticles in a pancreatic cancer cell line
- (2015) Xinzhe Yu et al. International Journal of Nanomedicine
- Gemcitabine-based therapy for pancreatic cancer using the squalenoyl nucleoside monophosphate nanoassemblies
- (2015) Andrei Maksimenko et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Preparation of intravenous injection nanoformulation of VESylated gemcitabine by co-assembly with TPGS and its anti-tumor activity in pancreatic tumor-bearing mice
- (2015) Yanyun Xu et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Self-assembled nanoscale coordination polymers carrying oxaliplatin and gemcitabine for synergistic combination therapy of pancreatic cancer
- (2015) Christopher Poon et al. JOURNAL OF CONTROLLED RELEASE
- Novel approaches in the management of pancreatic ductal adenocarcinoma: potential promises for the future
- (2015) Gaurav Goel et al. Journal of Hematology & Oncology
- Ribonucleotide reductase is an effective target to overcome gemcitabine resistance in gemcitabine-resistant pancreatic cancer cells with dual resistant factors
- (2015) Kentaro Minami et al. JOURNAL OF PHARMACOLOGICAL SCIENCES
- The oncogenic receptor ErbB2 modulates gemcitabine and irinotecan/SN-38 chemoresistance of human pancreatic cancer cells via hCNT1 transporter and multidrug-resistance associated protein MRP-2
- (2015) Nicolas Skrypek et al. Oncotarget
- Targeting the mRNA-binding protein HuR impairs malignant characteristics of pancreatic ductal adenocarcinoma cells
- (2015) Masaya Jimbo et al. Oncotarget
- Paracrine SDF-1α signaling mediates the effects of PSCs on GEM chemoresistance through an IL-6 autocrine loop in pancreatic cancer cells
- (2015) Hui Zhang et al. Oncotarget
- Gemcitabine-Based Chemogene Therapy for Pancreatic Cancer Using Ad-dCK::UMK GDEPT and TS/RR siRNA Strategies
- (2015) Soukaina Réjiba et al. NEOPLASIA
- Gene Expression Levels as Predictive Markers of Outcome in Pancreatic Cancer after Gemcitabine-Based Adjuvant Chemotherapy
- (2015) Hayato Fujita et al. NEOPLASIA
- Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival
- (2014) Berna C. Özdemir et al. CANCER CELL
- Stromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma
- (2014) Andrew D. Rhim et al. CANCER CELL
- Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
- (2014) L. Rahib et al. CANCER RESEARCH
- Stromal reengineering to treat pancreas cancer
- (2014) I. M. Stromnes et al. CARCINOGENESIS
- Vitamin D Receptor-Mediated Stromal Reprogramming Suppresses Pancreatitis and Enhances Pancreatic Cancer Therapy
- (2014) Mara H. Sherman et al. CELL
- Gemcitabine: Metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer
- (2014) Lucas de Sousa Cavalcante et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Preparation, optimization and in vitro characterization of stearoyl-gemcitabine polymeric micelles: A comparison with its self-assembled nanoparticles
- (2014) Zahra Daman et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Transport properties of pancreatic cancer describe gemcitabine delivery and response
- (2014) Eugene J. Koay et al. JOURNAL OF CLINICAL INVESTIGATION
- Application of ProTide Technology to Gemcitabine: A Successful Approach to Overcome the Key Cancer Resistance Mechanisms Leads to a New Agent (NUC-1031) in Clinical Development
- (2014) Magdalena Slusarczyk et al. JOURNAL OF MEDICINAL CHEMISTRY
- Establishment of human pancreatic cancer gemcitabine-resistant cell line with ribonucleotide reductase overexpression
- (2014) CONGFEI WANG et al. ONCOLOGY REPORTS
- Nab-Paclitaxel for Metastatic Pancreatic Cancer: Clinical Outcomes and Potential Mechanisms of Action
- (2014) Salah-Eddin Al-Batran et al. Oncology Research and Treatment
- Self-Assembling, Amphiphilic Polymer–Gemcitabine Conjugate Shows Enhanced Antitumor Efficacy Against Human Pancreatic Adenocarcinoma
- (2013) Deepak Chitkara et al. BIOCONJUGATE CHEMISTRY
- Comparative benefits of Nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancer
- (2013) N. Awasthi et al. CARCINOGENESIS
- The development of orally administrable gemcitabine prodrugs with d-enantiomer amino acids: Enhanced membrane permeability and enzymatic stability
- (2013) Yasuhiro Tsume et al. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
- A Starring Role for Stellate Cells in the Pancreatic Cancer Microenvironment
- (2013) Minoti V. Apte et al. GASTROENTEROLOGY
- Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in Gemcitabine or CO-101 Sensitivity
- (2013) Elizabeth Poplin et al. JOURNAL OF CLINICAL ONCOLOGY
- A Phase 1 Comparative Pharmacokinetic and Cardiac Safety Study of Two Intravenous Formulations of CO-101 in Patients With Advanced Solid Tumors
- (2013) F.E. Stuurman et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Imbalance of desmoplastic stromal cell numbers drives aggressive cancer processes
- (2013) Raghu Kadaba et al. JOURNAL OF PATHOLOGY
- Understanding the stroma of pancreatic cancer: co-evolution of the microenvironment with epithelial carcinogenesis
- (2013) Mert Erkan JOURNAL OF PATHOLOGY
- Pancreatic Cancer hENT1 Expression and Survival From Gemcitabine in Patients From the ESPAC-3 Trial
- (2013) William Greenhalf et al. JNCI-Journal of the National Cancer Institute
- The human concentrative and equilibrative nucleoside transporter families, SLC28 and SLC29
- (2013) James D. Young et al. MOLECULAR ASPECTS OF MEDICINE
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Macrophages mediate gemcitabine resistance of pancreatic adenocarcinoma by upregulating cytidine deaminase
- (2013) N Weizman et al. ONCOGENE
- CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer
- (2013) A. Neesse et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer
- (2013) C. Feig et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels
- (2013) Vikash P. Chauhan et al. Nature Communications
- DCK is frequently inactivated in acquired gemcitabine-resistant human cancer cells
- (2012) Yuriko Saiki et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- The effect of the acid-sensitivity of 4-(N)-stearoyl gemcitabine-loaded micelles on drug resistance caused by RRM1 overexpression
- (2012) Saijie Zhu et al. BIOMATERIALS
- A multicentre randomised phase II trial of gemcitabine alone vs gemcitabine and S-1 combination therapy in advanced pancreatic cancer: GEMSAP study
- (2012) Y Nakai et al. BRITISH JOURNAL OF CANCER
- Enzymatic Targeting of the Stroma Ablates Physical Barriers to Treatment of Pancreatic Ductal Adenocarcinoma
- (2012) Paolo P. Provenzano et al. CANCER CELL
- Overcoming nucleoside analog chemoresistance of pancreatic cancer: A therapeutic challenge
- (2012) Sau Wai Hung et al. CANCER LETTERS
- Targeted destruction of the orchestration of the pancreatic stroma and tumor cells in pancreatic cancer cases: Molecular basis for therapeutic implications
- (2012) Xiangyu Kong et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Levels of Gemcitabine Transport and Metabolism Proteins Predict Survival Times of Patients Treated With Gemcitabine for Pancreatic Adenocarcinoma
- (2012) Raphaël Maréchal et al. GASTROENTEROLOGY
- Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer
- (2012) Michael A Jacobetz et al. GUT
- Gemcitabine versus Modified Gemcitabine: A Review of Several Promising Chemical Modifications
- (2012) Elodie Moysan et al. MOLECULAR PHARMACEUTICS
- The role of stroma in pancreatic cancer: diagnostic and therapeutic implications
- (2012) Mert Erkan et al. Nature Reviews Gastroenterology & Hepatology
- The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family
- (2012) N Skrypek et al. ONCOGENE
- The Mucin MUC4 and Its Membrane Partner ErbB2 Regulate Biological Properties of Human CAPAN-2 Pancreatic Cancer Cells via Different Signalling Pathways
- (2012) Nicolas Jonckheere et al. PLoS One
- nab -Paclitaxel Potentiates Gemcitabine Activity by Reducing Cytidine Deaminase Levels in a Mouse Model of Pancreatic Cancer
- (2012) Kristopher K. Frese et al. Cancer Discovery
- Overcoming the stromal barrier: technologies to optimize drug delivery in pancreatic cancer
- (2012) Anastasios Dimou et al. Therapeutic Advances in Medical Oncology
- CNT1 Expression Influences Proliferation and Chemosensitivity in Drug-Resistant Pancreatic Cancer Cells
- (2011) Y. D. Bhutia et al. CANCER RESEARCH
- In vitro and in vivo anti-tumor activities of a gemcitabine derivative carried by nanoparticles
- (2011) Brian R. Sloat et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Stearoyl gemcitabine nanoparticles overcome resistance related to the over-expression of ribonucleotide reductase subunit M1
- (2011) Woon-Gye Chung et al. JOURNAL OF CONTROLLED RELEASE
- Enhanced antiproliferative activity of Herceptin (HER2)-conjugated gemcitabine-loaded chitosan nanoparticle in pancreatic cancer therapy
- (2011) Geetanjali Arya et al. Nanomedicine-Nanotechnology Biology and Medicine
- Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer
- (2011) Soukaina Réjiba et al. Nanomedicine-Nanotechnology Biology and Medicine
- Integrating pharmacogenetics into gemcitabine dosing—time for a change?
- (2011) Joseph Ciccolini et al. Nature Reviews Clinical Oncology
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Self-assembled nucleolipids: from supramolecular structure to soft nucleic acid and drug delivery devices
- (2011) V. Allain et al. NUCLEIC ACIDS RESEARCH
- Tumor-Selective Delivery of Macromolecular Drugs via the EPR Effect: Background and Future Prospects
- (2010) Hiroshi Maeda BIOCONJUGATE CHEMISTRY
- Long circulation and cytotoxicity of PEGylated gemcitabine and its potential for the treatment of pancreatic cancer
- (2010) Mallaredy Vandana et al. BIOMATERIALS
- Stromal biology and therapy in pancreatic cancer
- (2010) A. Neesse et al. GUT
- Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models
- (2010) Andries M. Bergman et al. INVESTIGATIONAL NEW DRUGS
- Systemic Administration of Polymeric Nanoparticle-Encapsulated Curcumin (NanoCurc) Blocks Tumor Growth and Metastases in Preclinical Models of Pancreatic Cancer
- (2010) Savita Bisht et al. MOLECULAR CANCER THERAPEUTICS
- Delivering nanomedicine to solid tumors
- (2010) Rakesh K. Jain et al. Nature Reviews Clinical Oncology
- Pancreatic cancer: understanding and overcoming chemoresistance
- (2010) Zhiwei Wang et al. Nature Reviews Gastroenterology & Hepatology
- Contribution of Thymidylate Synthase to Gemcitabine Therapy for Advanced Pancreatic Cancer
- (2010) Shuji Komori et al. PANCREAS
- pp32 (ANP32A) Expression Inhibits Pancreatic Cancer Cell Growth and Induces Gemcitabine Resistance by Disrupting HuR Binding to mRNAs
- (2010) Timothy K. Williams et al. PLoS One
- Combinatorial Drug Conjugation Enables Nanoparticle Dual-Drug Delivery
- (2010) Santosh Aryal et al. Small
- Preparation of albumin nanospheres loaded with gemcitabine and their cytotoxicity against BXPC-3 cells in vitro
- (2009) Jin-ming Li et al. ACTA PHARMACOLOGICA SINICA
- Pancreatic cancer cells resistance to gemcitabine: the role of MUC4 mucin
- (2009) S Bafna et al. BRITISH JOURNAL OF CANCER
- The Role of HuR in Gemcitabine Efficacy in Pancreatic Cancer: HuR Up-regulates the Expression of the Gemcitabine Metabolizing Enzyme Deoxycytidine Kinase
- (2009) C. L. Costantino et al. CANCER RESEARCH
- Human Equilibrative Nucleoside Transporter 1 and Human Concentrative Nucleoside Transporter 3 Predict Survival after Adjuvant Gemcitabine Therapy in Resected Pancreatic Adenocarcinoma
- (2009) R. Marechal et al. CLINICAL CANCER RESEARCH
- Clinical pharmacology and pharmacogenetics of gemcitabine
- (2009) Andrea Wong et al. DRUG METABOLISM REVIEWS
- Is the resistance of gemcitabine for pancreatic cancer settled only by overexpression of deoxycytidine kinase?
- (2009) Funamizu ONCOLOGY REPORTS
- Gemcitabine chemoresistance in pancreatic cancer: Molecular mechanisms and potential solutions
- (2009) Roland Andersson et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Targeted Delivery of Gemcitabine to Pancreatic Adenocarcinoma Using Cetuximab as a Targeting Agent
- (2008) C. R. Patra et al. CANCER RESEARCH
- Gemcitabine Resistance in Pancreatic Cancer: Picking the Key Players
- (2008) M. P. Kim et al. CLINICAL CANCER RESEARCH
- Human Equilibrative Nucleoside Transporter 1 Levels Predict Response to Gemcitabine in Patients With Pancreatic Cancer
- (2008) James J. Farrell et al. GASTROENTEROLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search